Aktienanalyse zu SeaStar Medical Holding Corp (ICU)ICUSeaStar Medical Holding Corp

SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA). It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

SeaStar Medical (ICU) is currently a hold. The stock is trading at $3.09, significantly below the analyst price target of $8, indicating potential upside. However, the RSI is at 31.054, suggesting the stock is oversold, which could lead to a short-term rebound. The company reported a gross margin of 90.71% in Q1 2026, showing strong profitability on sales, but it has a concerning net income loss of $3.73 million in Q2 2026, which poses a risk to long-term investment.